Prospect and progress of oncolytic viruses for treating peripheral nerve sheath tumors.
Prospect and progress of oncolytic viruses for treating peripheral nerve sheath tumors.
复制标题
DOI：
10.1517/21678707.2016.1128322
复制
发表时间：
2016
影响因子：
0.8
通讯作者：
Rabkin SD
中科院分区：
文献类型：
--
作者：
Antoszczyk S;Rabkin SD
周围神经鞘瘤（PNST）是一组起源于神经外胚层并在周围神经中生长的肿瘤。恶性转化导致预后不良并且通常是致命的。目前 PNST 的治疗主要是手术治疗，通常不完全或伴有明显的功能丧失，同时结合放疗和/或化疗，其效果尚无定论。溶瘤病毒（OV）可有效杀死肿瘤细胞，同时对正常组织保持安全，是一种针对 PNST 患者的新型抗肿瘤疗法。由于当前治疗的疗效较低，因此需要针对 PNST 的新疗法。临床前，OVs 已证明治疗 PNST 和神经周围肿瘤侵袭的功效以及安全性。我们将讨论各种 PNST 及其临床前模型，以及正在测试其治疗效果的 OV，包括溶瘤单纯疱疹病毒 (HSV)、腺病毒 (Ad) 和麻疹病毒 (MV)。 OVs可以“武装”以表达治疗性转基因或与其他疗法结合以增强其活性。 PNST 模型中 OV 的临床前测试已经证明了其治疗潜力，并为临床转化提供了支持。其他实体瘤的临床研究提供了证据，证明 OV 对患者是安全且有效的。最近成功完成溶瘤HSV III期临床试验，为溶瘤病毒疗法进入临床实践铺平了道路。
Peripheral nerve sheath tumors (PNSTs) are an assorted group of neoplasms originating from neuroectoderm and growing in peripheral nerves. Malignant transformation leads to a poor prognosis and is often lethal. Current treatment of PNSTs is predominantly surgical, which is often incomplete or accompanied by significant loss of function, in conjunction with radiotherapy and/or chemotherapy, for which the benefits are inconclusive. Oncolytic viruses (OVs) efficiently kill tumor cells while remaining safe for normal tissues, and are a novel antitumor therapy for patients with PNSTs. Because of the low efficacy of current treatments, new therapies for PNSTs are needed. Pre-clinically, OVs have demonstrated efficacy in treating PNSTs and perineural tumor invasion, as well as safety. We will discuss the various PNSTs and their preclinical models, and the OVs being tested for their treatment, including oncolytic herpes simplex virus (HSV), adenovirus (Ad), and measles virus (MV). OVs can be ‘armed’ to express therapeutic transgenes or combined with other therapeutics to enhance their activity. Preclinical testing of OVs in PNST models has demonstrated their therapeutic potential and provided support for clinical translation. Clinical studies with other solid tumors have provided evidence that OVs are safe in patients and efficacious. The recent successful completion of a phase III clinical trial of oncolytic HSV paves the way for oncolytic virotherapy to enter clinical practice.
登录
查看更多内容
影响因子：
15.9
作者：
Antoszczyk, Slawomir;Spyra, Melanie;Rabkin, Samuel D.
通讯作者：
Rabkin, Samuel D.
影响因子：
3.5
作者：
Deyle, David R.;Escobar, Diana Zarate;Babovic-Vuksanovic, Dusica
通讯作者：
Babovic-Vuksanovic, Dusica
影响因子：
3.9
作者：
Hagel, Christian;Zils, Ulrich;Mautner, Victor Felix
通讯作者：
Mautner, Victor Felix
影响因子：
10.1
作者：
Chiocca EA;Rabkin SD
通讯作者：
Rabkin SD
影响因子：
4.2
作者：
Geevarghese, Sunil K.;Geller, David A.;Tawfik, Hoda
通讯作者：
Tawfik, Hoda